| abstract |
The present invention relates to 1- [2- (2-chloro-4-{[(R) -2-hydroxy-2- (8-hydroxy-2-oxo-1,2-dihydroquinoline) biphenyl-2-ylcarbamate -5-yl) ethylamino] methyl} -5-methoxyphenylcarbamoyl) ethyl] piperidin-4-yl ester, or a pharmaceutically acceptable salt thereof, and a pharmaceutical combination comprising fluticasone furan carboxylate ester, and for example There is provided the use of a combination of agents in the treatment or prevention of lung disorders such as respiratory disorders or diseases such as chronic obstructive pulmonary disease (COPD), asthma and asthma-COPD overlap syndrome (ACOS). [Selection figure] None |